JP7183149B2 - 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用 - Google Patents

安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用 Download PDF

Info

Publication number
JP7183149B2
JP7183149B2 JP2019512267A JP2019512267A JP7183149B2 JP 7183149 B2 JP7183149 B2 JP 7183149B2 JP 2019512267 A JP2019512267 A JP 2019512267A JP 2019512267 A JP2019512267 A JP 2019512267A JP 7183149 B2 JP7183149 B2 JP 7183149B2
Authority
JP
Japan
Prior art keywords
protein
amino acid
seq
influenza
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019512267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537424A5 (enExample
JP2019537424A (ja
Inventor
ジェフリー・シー・ボイントン
バーニー・エス・グレアム
ジョン・アール・マスコラ
ハディ・エム・ヤシン
キズメキア・エス・コーベット
サイエド・エム・モイン
リンシュー・ワン
優 兼清
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of JP2019537424A publication Critical patent/JP2019537424A/ja
Publication of JP2019537424A5 publication Critical patent/JP2019537424A5/ja
Priority to JP2022186724A priority Critical patent/JP7500692B2/ja
Application granted granted Critical
Publication of JP7183149B2 publication Critical patent/JP7183149B2/ja
Priority to JP2024091170A priority patent/JP2024123036A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nanotechnology (AREA)
JP2019512267A 2016-09-02 2017-09-01 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用 Active JP7183149B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022186724A JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2024091170A JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383267P 2016-09-02 2016-09-02
US62/383,267 2016-09-02
PCT/US2017/049894 WO2018045308A1 (en) 2016-09-02 2017-09-01 Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022186724A Division JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用

Publications (3)

Publication Number Publication Date
JP2019537424A JP2019537424A (ja) 2019-12-26
JP2019537424A5 JP2019537424A5 (enExample) 2020-09-17
JP7183149B2 true JP7183149B2 (ja) 2022-12-05

Family

ID=59887401

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019512267A Active JP7183149B2 (ja) 2016-09-02 2017-09-01 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2022186724A Active JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2024091170A Pending JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022186724A Active JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2024091170A Pending JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用

Country Status (11)

Country Link
US (3) US11338033B2 (enExample)
EP (1) EP3506938A1 (enExample)
JP (3) JP7183149B2 (enExample)
KR (2) KR20190056382A (enExample)
CN (2) CN110167585B (enExample)
AU (2) AU2017321883B2 (enExample)
BR (1) BR112019004189A2 (enExample)
CA (1) CA3035443A1 (enExample)
IL (3) IL265121B2 (enExample)
SG (2) SG10201912944QA (enExample)
WO (1) WO2018045308A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3054971B1 (en) 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
CN110167585B (zh) * 2016-09-02 2024-03-08 美国卫生与公众服务部 稳定化的第2组流感血凝素茎区三聚体及其用途
GB2578163A (en) * 2018-10-19 2020-04-22 Univ Pretoria Plant produced avian influenza antigens and their uses in diagnostic assays and devices
CN113423718A (zh) 2019-02-08 2021-09-21 美国政府(由卫生和人类服务部的部长所代表) 基于纳米颗粒的流感病毒疫苗及其用途
EP4110384A4 (en) * 2020-02-26 2024-07-31 The Wistar Institute of Anatomy and Biology COMPOSITIONS CONTAINING SELF-ASSEMBLING VACCINES AND METHODS OF USE THEREOF
CN111560074B (zh) * 2020-03-20 2021-07-09 中山大学 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
US20240165224A1 (en) 2021-03-26 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP4313152A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
US20250281595A1 (en) 2021-06-28 2025-09-11 Glaxosmithkline Biologicals Sa Novel influenza antigens
AU2022345984A1 (en) * 2021-09-16 2024-04-04 Emergent Product Development Gaithersburg Inc. Vaccine compositions
WO2023061993A1 (en) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2024131862A1 (zh) * 2022-12-22 2024-06-27 北京吉诺卫生物科技有限公司 一种rsv疫苗及其制备方法与应用
CN115850396B (zh) * 2022-12-22 2024-02-06 北京吉诺卫生物科技有限公司 一种rsv纳米颗粒疫苗及其制备方法与应用
WO2024163912A2 (en) * 2023-02-03 2024-08-08 The Children's Medical Center Corporation Vaccine and therapeutic protein delivery compositions comprising fusion proteins
WO2024167855A1 (en) 2023-02-06 2024-08-15 Emergent Product Development Gaithersburg Inc. Influenza hemagglutinin constructs and compositions
WO2024197134A1 (en) * 2023-03-21 2024-09-26 President And Fellows Of Harvard College Coronavirus spike protein-based vaccines

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013044203A2 (en) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
JP2015502353A (ja) 2011-11-28 2015-01-22 クルセル ホランド ベー ヴェー インフルエンザウイルスワクチンおよびその使用
JP2015519348A (ja) 2012-05-23 2015-07-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ インフルエンザワクチン構築物
WO2015183969A1 (en) 2014-05-27 2015-12-03 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
JP2016525889A (ja) 2013-05-30 2016-09-01 クルセル ホランド ベー ヴェー インフルエンザウイルスワクチンおよびその使用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
CA2462455C (en) 2001-10-01 2012-07-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
US7097841B2 (en) 2002-05-10 2006-08-29 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
AU2003246690B2 (en) * 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
CN102268094A (zh) * 2002-08-30 2011-12-07 比奥雷克西斯药物公司 被修饰的转铁蛋白抗体的融合蛋白
EP1633312A4 (en) 2003-06-16 2012-09-26 Medimmune Llc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
GB0319797D0 (en) 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US7897408B2 (en) 2005-09-12 2011-03-01 Japan Science And Technology Agency Method for producing CdS-apoferritin and ZnS-apoferritin complexes
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
MX2009007106A (es) 2006-12-29 2010-04-30 Inst Pasteur Of Shanghai Lentivirus pseudotipificado con hemaglutinina de influenza y metodos de uso.
US20080299151A1 (en) 2007-05-31 2008-12-04 Statens Serum Institut Influenza vaccines
WO2008157419A2 (en) 2007-06-13 2008-12-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides of influenza virus
CA2696764A1 (en) 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
WO2009109428A2 (en) 2008-02-01 2009-09-11 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
JP5382489B2 (ja) 2008-03-29 2014-01-08 国立大学法人 奈良先端科学技術大学院大学 円偏光発光性ナノ微粒子
US20110177122A1 (en) 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
SI3354657T1 (sl) 2009-09-22 2022-05-31 Medicago Inc. Postopek za pripravo iz rastlin izpeljanih beljakovin
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
WO2011102900A1 (en) 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
AU2011344126B2 (en) * 2010-12-13 2016-11-10 The University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
EP2758075B1 (en) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
EP2934581B1 (en) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
EP3054971B1 (en) 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
SI3063273T1 (sl) 2013-10-28 2020-03-31 Blue Sky Vaccines Gmbh Vektor virusa gripe za viroterapijo
KR102463632B1 (ko) * 2014-07-10 2022-11-03 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
TWI720946B (zh) 2014-08-08 2021-03-11 美商Ｖｌｐ醫療股份有限公司 包含改質套膜蛋白質ｅ３之類病毒粒子
BR112017014219A2 (en) 2014-12-31 2018-03-06 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services multivalent nanoparticle-based vaccines
EP3474893A1 (en) 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
CN110167585B (zh) * 2016-09-02 2024-03-08 美国卫生与公众服务部 稳定化的第2组流感血凝素茎区三聚体及其用途
WO2021231729A1 (en) * 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013044203A2 (en) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
JP2015502353A (ja) 2011-11-28 2015-01-22 クルセル ホランド ベー ヴェー インフルエンザウイルスワクチンおよびその使用
JP2015519348A (ja) 2012-05-23 2015-07-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ インフルエンザワクチン構築物
JP2016525889A (ja) 2013-05-30 2016-09-01 クルセル ホランド ベー ヴェー インフルエンザウイルスワクチンおよびその使用
WO2015183969A1 (en) 2014-05-27 2015-12-03 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YASSINE H M; ET AL，HEMAGGLUTININ-STEM NANOPARTICLES GENERATE HETEROSUBTYPIC INFLUENZA PROTECTION，NATURE MEDICINE，英国，NATURE PUBLISHING GROUP，2015年09月，VOL:21, NR:9，PAGE(S):1065 - 1070，http://dx.doi.org/10.1038/nm.3927

Also Published As

Publication number Publication date
CN110167585A (zh) 2019-08-23
EP3506938A1 (en) 2019-07-10
IL303650A (en) 2023-08-01
WO2018045308A1 (en) 2018-03-08
US11338033B2 (en) 2022-05-24
IL265121A (enExample) 2019-04-30
JP2023018073A (ja) 2023-02-07
JP2024123036A (ja) 2024-09-10
BR112019004189A2 (pt) 2019-06-25
US11793871B2 (en) 2023-10-24
CN118146389A (zh) 2024-06-07
CA3035443A1 (en) 2018-03-08
US12527857B2 (en) 2026-01-20
IL303650B2 (en) 2025-02-01
AU2022246465A1 (en) 2022-11-17
AU2017321883B2 (en) 2022-07-07
JP7500692B2 (ja) 2024-06-17
IL315821A (en) 2024-11-01
SG11201901790YA (en) 2019-03-28
US20240050554A1 (en) 2024-02-15
SG10201912944QA (en) 2020-02-27
AU2022246465B2 (en) 2024-05-30
US20220339278A1 (en) 2022-10-27
CN110167585B (zh) 2024-03-08
KR20190056382A (ko) 2019-05-24
AU2017321883A1 (en) 2019-04-18
US20190192651A1 (en) 2019-06-27
KR20240042570A (ko) 2024-04-02
JP2019537424A (ja) 2019-12-26
IL265121B2 (en) 2023-11-01
IL265121B1 (en) 2023-07-01
IL303650B1 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
AU2022246465B2 (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
US12268737B2 (en) Stabilized influenza hemagglutinin stem region trimers and uses thereof
US10137190B2 (en) Nucleic acid molecules encoding ferritin-hemagglutinin fusion proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200806

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221122

R150 Certificate of patent or registration of utility model

Ref document number: 7183149

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250